التفاصيل البيبلوغرافية
| العنوان: |
DataSheet_5_Immunophenotyping Reveals Longitudinal Changes in Circulating Immune Cells During Radium-223 Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer.pdf |
| المؤلفون: |
Jeroen H. A. Creemers (9561569), Maarten J. van der Doelen (10813803), Sandra van Wilpe (10813806), Rick Hermsen (10813809), Tjitske Duiveman-de Boer (6197000), Diederik M. Somford (8568981), Marcel J. R. Janssen (10813812), J. P. Michiel Sedelaar (8568987), Niven Mehra (7867451), Johannes Textor (610955), Harm Westdorp (3478268) |
| سنة النشر: |
2021 |
| المجموعة: |
Smithsonian Institution: Digital Repository |
| مصطلحات موضوعية: |
Cancer, Cancer Cell Biology, Cancer Diagnosis, Cancer Genetics, Cancer Therapy (excl. Chemotherapy and Radiation Therapy), Chemotherapy, Haematological Tumours, Molecular Targets, Radiation Therapy, Solid Tumours, Oncology and Carcinogenesis not elsewhere classified, metastatic castration-resistant prostate cancer (mCRPC), immune checkpoints, radionuclide therapy, radium-223, immunophenotyping |
| الوصف: |
Background Radium-223 improves overall survival (OS) in men with bone metastatic castration-resistant prostate cancer (mCRPC). While the exact mechanism behind this survival benefit remains unclear, radium-induced immunological mechanisms might contribute to the OS advantage. We performed a comprehensive evaluation of the immunological changes in mCRPC patients by phenotyping the peripheral blood mononuclear cells (PBMCs) during radium-223 therapy. Materials and Methods In this prospective, single-arm, exploratory study, PBMCs of 30 mCRPC patients were collected before, during, and after treatment with radium-223. Lymphocyte and monocyte counts were analyzed to get insight into general immune cell trends. Next, we analyzed changes in T cell subsets, myeloid-derived suppressor cells (MDSCs), and immune checkpoint expression using linear regression models. Per subset, the 6-month change (% of baseline) was determined. Bootstrapped 95% confidence intervals were used to measure the degree of uncertainty of our findings. Results We observed a substantial decrease in absolute lymphocyte counts (-0.12 * 10^9 cells/L per injection, 95% CI: -0.143 - -0.102). Simultaneously, an increase was observed in the proportion of T cells that expressed costimulatory (ICOS) or inhibitory (TIM-3, PD-L1, and PD-1) checkpoint molecules. Moreover, the fraction of two immunosuppressive subsets – the regulatory T cells and the monocytic MDSCs – increased throughout treatment. These findings were not more pronounced in patients with an alkaline phosphatase response during therapy. Conclusion Immune cell subsets in patients with mCRPC changed during radium-223 therapy, which warrants further research into the possible immunological consequences of these changes. |
| نوع الوثيقة: |
dataset |
| اللغة: |
unknown |
| العلاقة: |
https://figshare.com/articles/dataset/DataSheet_5_Immunophenotyping_Reveals_Longitudinal_Changes_in_Circulating_Immune_Cells_During_Radium-223_Therapy_in_Patients_With_Metastatic_Castration-Resistant_Prostate_Cancer_pdf/14609574Test |
| DOI: |
10.3389/fonc.2021.667658.s005 |
| الإتاحة: |
https://doi.org/10.3389/fonc.2021.667658.s005Test |
| حقوق: |
CC BY 4.0 |
| رقم الانضمام: |
edsbas.BDE99AF7 |
| قاعدة البيانات: |
BASE |
